Augment phase III study: Lenalidomide/rituximab (R2) improved efficacy over rituximab/placebo in relapsed/refractory follicular patients irrespective of POD24 status

This article has no abstract
Epistemonikos ID: 5bfd7558ab95686eac8f02fb3c435e1dc072cabb
First added on: Feb 11, 2025